[HTML][HTML] Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

EWFW Alton, DK Armstrong, D Ashby… - The Lancet …, 2015 - thelancet.com
Background Lung delivery of plasmid DNA encoding the CFTR gene complexed with a
cationic liposome is a potential treatment option for patients with cystic fibrosis. We aimed to …

Gene therapy in cystic fibrosis

DK Armstrong, S Cunningham, JC Davies… - Archives of disease in …, 2014 - adc.bmj.com
The principal cause of morbidity and mortality in cystic fibrosis (CF) is pulmonary disease, so
the focus of new treatments in this condition is primarily targeted at the lungs. Since the …

[HTML][HTML] A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene …

EWFW Alton, DK Armstrong, D Ashby, KJ Bayfield… - 2016 - europepmc.org
Background Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the
CF transmembrane conductance regulator (CFTR) gene leading to abnormal airway surface …

Effect of high-flow nasal cannula therapy vs continuous positive airway pressure therapy on liberation from respiratory support in acutely ill children admitted to …

P Ramnarayan, A Richards-Belle, L Drikite, M Saull… - JAMA, 2022 - jamanetwork.com
Importance The optimal first-line mode of noninvasive respiratory support for acutely ill
children is not known. Objective To evaluate the noninferiority of high-flow nasal cannula …

[HTML][HTML] Methods: clinical trial design and outcome measures

EWFW Alton, DK Armstrong, D Ashby… - A randomised, double …, 2016 - ncbi.nlm.nih.gov
Methods: clinical trial design and outcome measures - A randomised, double-blind, placebo-controlled
trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance …

[HTML][HTML] Introduction and background

EWFW Alton, DK Armstrong, D Ashby… - A randomised, double …, 2016 - ncbi.nlm.nih.gov
Introduction and background - A randomised, double-blind, placebo-controlled trial of repeated
nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene …

[HTML][HTML] Results of clinical efficacy outcomes

EWFW Alton, DK Armstrong, D Ashby… - A randomised, double …, 2016 - ncbi.nlm.nih.gov
Results of clinical efficacy outcomes - A randomised, double-blind, placebo-controlled trial
of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) …

[HTML][HTML] Results of mechanistic substudy

EWFW Alton, DK Armstrong, D Ashby… - A randomised, double …, 2016 - ncbi.nlm.nih.gov
Results of mechanistic substudy - A randomised, double-blind, placebo-controlled trial of
repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) …

[CITATION][C] Clinical role of lung clearance index in the assessment of cystic fibrosis lung disease

DK Armstrong - 2019 - era.ed.ac.uk
Clinical role of lung clearance index in the assessment of cystic fibrosis lung disease Edinburgh
Research Archive logo Edinburgh Research Archive University of Edinburgh homecrest Toggle …

[CITATION][C] Assessment of immune responses to single and repeat dose aeroslisation of the non-viral formualtion PGM169/GL67A in cystic fibrosis patients

U Griesenbach, EWFW Alton… - HUMAN …, 2014 - MARY ANN LIEBERT, INC 140 …